Prof. Timothy Illidge is a Professor of Targeted Therapy and Oncology at the University of Manchester and an Honorary Consultant in Clinical Oncology at Christie Hospital NHS Foundation Trust.

After graduating with a BSc in Biochemistry from London University, he completed his medical training (MB BS) at Guy's Hospital Medical School, London. He was later awarded a PhD from the University of Southampton. Prof. Illidge completed a Cancer Research UK (CRUK) fellowship and was appointed Senior Lecturer and Honorary Consultant in Oncology at Southampton University Hospitals NHS Trust in 1999. In 1998, he was awarded another fellowship at Stanford University in California, where he worked as part of the lymphoma team. In 2004, he moved his CRUK research group to the Manchester Institute and The Christie.

Prof. Illidge is internationally renowned for his research into lymphoma and has been extensively published. He has served as the principal investigator for numerous early-phase and late clinical trials and is a member of the central steering group of the NCRI lymphoma group. He also leads a CRUK and Leukaemia & Lymphoma Research funded translational research group, which focuses on taking new approaches in the treatment of lymphoma from the bench to bedside. Additionally, he is one of the medical experts for the Lymphoma Association and CRUK and is frequently invited to speak at international workshops on lymphoma.

His areas of expertise include chemotherapy, immunotherapy, and radiotherapy. He treats a range of conditions, including bladder cancer, Hodgkin lymphoma, lymphoma, and non-Hodgkin lymphoma. Prof. Illidge has been with the University of Manchester and Christie Hospital NHS Foundation Trust since 2004, contributing significantly to advancements in oncology and targeted therapy.